MedTrace Logo

SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme

NCT00003293 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2012-09-11

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether SU-101 is more effective than procarbazine in treating patients with glioblastoma multiforme.

PURPOSE: Randomized phase III trial to compare the effectiveness of SU-101 with that of procarbazine in treating patients with glioblastoma multiforme that has recurred.

Conditions

Interventions

DRUG

leflunomide

DRUG

procarbazine hydrochloride

Sponsors & Collaborators

Principal Investigators

  • Alison L. Hannah, MBBS · SUGEN

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-02-28
Primary Completion
2001-05-31
Completion
2001-05-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003293 on ClinicalTrials.gov